Navigation Links
TGen and George Mason University announce precision medicine alliance to benefit patients
Date:5/6/2014

PHOENIX, Ariz. and FAIRFAX, Va. May 6, 2014 The Translational Genomics Research Institute (TGen) and George Mason University today announced the creation of a strategic research alliance to benefit patients with cancer and other life-threatening illnesses.

The TGen-George Mason Molecular Medicine Alliance is a groundbreaking effort in precision medicine, which recommends to clinicians the best medications and treatments based on each patient's molecular profile.

Both institutions are world leaders in exploring the underlying fundamentals of disease by studying genes and proteins. By combining efforts, George Mason and TGen look to develop a more precise research strategy to help people afflicted by cancer and other diseases, while pursuing additional research. The alliance is the first of its kind in the field.

TGen, at the heart of Phoenix's Biomedical Campus, is recognized as a pioneer in studying genomics, or DNA, to uncover the underlying molecular causes of disease. Mason, strategically located outside the nation's capital, has one of the world's most advanced labs for studying proteins: the Center for Applied Proteomics and Molecular Medicine.

The alliance already has submitted applications for more than $12 million in research grants for projects that each institution might not have pursued alone, but are now well positioned to accomplish by combining their complimentary expertise.

"This is a timely and exceptionally forward looking research effort between George Mason University and TGen. The Molecular Medicine Alliance is an opportunity for two highly regarded institutions to integrate their complementary knowledge and human resources to help patients by using state-of-the-art technology to advance new therapeutics options," said Dr. Jeffrey Trent, TGen President and Research Director.

"This is a major achievement for science and health care," said Dr. ngel Cabrera, President of Mason. "By joining forces, researchers can understand disease at a more refined level and more people can be helped. This is the level of research that all universities and companies strive to achieve."

Both institutions embrace translational medicine moving new laboratory discoveries as quickly as possible into new treatments for patients. Both institutions pursue precision medicine recommending the best medication based on each patient's molecular profile.

The alliance extends both Mason's and TGen's footholds to the other sides of the nation, expanding each other's network of collaborators and clinical trials, and advancing new treatments to the public.

Using genomics to sort out genetic changes that lead to disease, TGen has conducted extensive clinical trials that have led to new treatments approved by the U.S. Food and Drug Administration (FDA). Using that model, Mason has the opportunity to use proteomics to develop new FDA approved treatments, including finding new uses for already approved FDA drugs.

By integrating genomics and proteomics, the alliance will initially focus on discoveries in four specific areas of research:

  • New treatments for patients with breast cancer or melanoma.
  • Treatments for patients with breast cancer that has spread to the bone and brain.
  • Biomarkers that can help diagnose traumatic injuries, such as brain concussions.
  • Developing a better understanding of infectious diseases and the human immune system, leading to new vaccines.

Through the alliance, Mason and TGen will have the opportunity to develop new discoveries, benefitting patients through new technologies. Mason students will have opportunities to intern at TGen. And the partners hope the alliance will have significant economic impact, creating jobs and new commercial businesses both in Arizona and Virginia.

The alliance will be celebrated at an event Friday, May 9, in the Mason Inn, Junior Ballroom on the Mason campus in Fairfax, Va.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Georgetown physician leads national resveratrol study for Alzheimers disease
2. James George, MD: 2012 ASH Wallace H. Coulter Award for Lifetime Achievement in Hematology
3. George Mason University researchers target breast cancer in 3 trials
4. Allied Minds and The George Washington University partner to form LuxCath LLC
5. Worldwide Internet Sensation and Ashland Musician George Dennehy Performs at the Science Museum of Virginia
6. Houston Rodeo Tickets: Official Onsales for Bruno Mars, George Strait, Blake Shelton, Luke Bryan, Pitbull, Zac Brown Band, Toby, Keith & Tim McGraw on Sat. Jan. 12th
7. Rushfit Ultimate Home Fitness: Review Examining George St Pierre’s Program Released
8. Georgetown and Temple Oral Surgeon at Austin Oral Surgery Donates to Local School
9. Dental Plus Management LLC, Welcomes Dr. George Daszko to DentalDeal.com
10. The George Washington University will hold symposium on Latino health disparities
11. Hydrotherapy Course Featuring HydroWorx Pool at St. George’s Park National Football Centre
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under Dr. ... board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program ... delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in ... and decide to donate. , “Women’s Hospital at Renaissance has been a collection ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... 2017 , ... Bill Howe started his sewer and drain company in 1980 ... joined the team, the Bill Howe brand was born and they began cultivating their ... back to the San Diego community in which they worked, lived and were raising ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology: